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Abstract 
Purpose: To evaluate the antiviral potential of a tetranortriterpenoid, gedunin, against dengue virus 
(DENV) replication by targeting the host chaperone, Hsp90.  
Methods: The compound, gedunin, was tested against the replication of DENV in vitro using BHK-15 
cells transfected with DENV-2 subgenomic replicon. Molecular docking of gedunin with Hsp90 protein 
was performed for evaluation of mode of action, using the program, Autodock vina. 
Results: In vitro antiviral data showed that gedunin significantly (p < 0.05) reduced DENV replication 
with EC50 of 10 µM. Further, in silico molecular docking data revealed strong interaction of gedunin with 
the ATP/ADP binding site of the host protein, Hsp90, with an estimated average free binding energy of -
8.9 kcal/mol.  
Conclusion: The results validate gedunin as a potential antiviral candidate. Further in vitro assays and 
in vivo viral challenge studies are required to confirm the exact mode of action and pharmacological 
profile of gedunin in DENV infections. 
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Dengue virus belongs to the family Flaviviridae 
and has recently emerged as a significant human 
pathogen causing 50-100 million infections per 
year globally [1]. Due to complexity of the 
immune response towards vaccines and the 
need to control the four virus serotypes 
simultaneously, the development of vaccines has 
been challenging [2]. Several studies have 
previously suggested that both viral and host 
proteins essential for viral replication can be 
exploited for antiviral development [1]. Like many 
cellular proteins, the viral proteins also require 
host chaperones as support for proper functions 
[3]. Hsp90 is an ATP dependent heat shock 
protein, which is highly conserved among many 
species from yeast to humans and involved in 
the regulation of several signaling, oncogenic 
and cell cycle protein [4,5]. The dependence of 
several oncogenes and other signaling 
processes involved in cancer progression on 
Hsp90 makes it a potential target against 
cancers [6,7]. It was shown that gedunin as an 
anticancer agent inhibits the function of Hsp90 
protein, resulting in the degradation and improper 
functioning of the client proteins, similar to other 
Hsp90 inhibitors [8].  Numerous Hsp90 inhibitors, 
identified as anticancer agents such as radicicol, 
geldanamycin (GA), and GA derivatives, block 
Hsp90 activity by binding to the N-terminal ATP 
pocket of the protein and inhibiting ATPase 
activity [9].  Geldanamycin was shown to be 
active against replication of a range of viruses, 
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including herpes simplex virus type 1 (HSV-1), 
severe acute respiratory syndrome coronavirus 
and Zaire EBOV in vitro [10,11]. 
 
It has been observed for several viruses, 
including Ebola, Influenza, DENV, and Japanese 
encephalitis virus (JEV), that many proteins of 
these viruses require Hsp90 for their folding, 
assembly, and maturation, making it an attractive 
target for antiviral development [3]. Other studies 
have suggested that Hsp90 also binds to the viral 
components mainly to the RNA polymerase 
affecting the assembly and nuclear transport of 
polymerase [12]. Researchers have found a 
tetranortriterpenoid compound called gedunin, 
obtained from the Indian neem tree (Azadirachta 
indica), to be active against the 90 kDa Hsp90 by 
binding directly to its helper protein p23 leading 
to its inactivation [13,14]. Neem has been found 
to possess antiviral activity against DENV, Ebola 
virus and coxsackie B virus, a group of 
enteroviruses [15]. Furthermore, in vitro studies 
and high throughput assays with gedunin and 
gedunin derivatives confirmed that these 
compounds inhibit Ebola virus replication and 
protein expression as well as their host cell 
binding [16]. However, the mechanism by which 
gedunin disrupts the function of Hsp90 or its 
client proteins consequently leading to reduction 
of viral replication in cell cultures, is still not 
completely understood. This study was 
conducted to evaluate the inhibitory potential of 
gedunin against DENV-2 replicon in cell culture. 
Further, molecular docking was performed in 
order to investigate the possible interaction of 
gedunin with Hsp90. The results of this study will 
aid in the development of more effective 




Cell culture, replicon construct and test 
compound 
 
BHK-15 cells were grown in minimal essential 
medium (MEM) containing 10 % fetal bovine 
serum (FBS) at 37°C incubator in the presence 
of 5 % CO2. DENV-2 replicon containing the non-
structural genes and R. luciferase as a reporter 
was used for the replicon assays to test the 
compound against dengue replication. The 
replicon construct and the compound were 
obtained from the Department of Biological 
Sciences, Purdue University, Indiana, USA. The 
test compound, gedunin, was suspended in 
DMSO and four dilutions (1, 10, 50 and 100 µM) 
of the compound based on the efficacy of these 
concentrations were tested against DENV 
replicon in vitro in BHK cells.  
 
RNA transcription and electroporation 
 
E. coli DH5-α cells were transformed with 
DENV2-R.luc-Rep, transformed colonies were 
inoculated in LB media containing 100 µg 
ampicillin overnight in a 37 °C shaking incubator. 
Plasmid DNA was purified using midiprep 
(Qiagen) kit and linearized by Xba-I digestion. 
Linearized DNA was purified with GFx columns 
and used as template for in vitro transcription 
using T7 RNA polymerase. Replicon RNA was 
purified with the RNeasy kit (Qiagen).  
 
For RNA electroporation, 2×106 BHK cells were 
washed twice before being resuspended in 0.4 
ml of room temperature PBS containing 10 - 20 
µg of RNA. The cells were pulsed twice 
consecutively, using the electroporation 
apparatus (BioRad Gene-Pulser II), at 25 µF, 1.5 
kV, and 200 Ohms in a 0.2 cm cuvette. 
Electroporated cells were incubated at room 
temperature for 3 min and 1 mL of 2.5 % FBS-
MEM was added to the cells. Cells were 
resuspended and the contents of the cuvette 
were then transferred to 9 mL of 2.5 % FBS-
MEM. The cells were mixed well, plated into a 
96-well plate (100 µl per well) and incubated in a 




After 2 h of incubation, media was aspirated off 
from the electroporated cells in a 96 wells plate 
and drug dilutions were added at final 
concentrations of 1, 10, 50 and 100 µM in 2.5 % 
FBS-MEM, while 1 % DMSO and untreated cells 
were used as negative controls. Three replicates 
were used for each dilution. Cells were grown at 




The cell extracts were taken at 48 h post-
infection, washed with PBS and then lysed with 
Renilla luciferase lysis buffer. These cells were 
incubated at room temperature for 30 min with 
gentle rocking and stored at -80 °C till further 
use. Luciferase activity was measured using 
standard Promega's Renilla luciferase assay 
system. The frozen extracts (lysates) were 
thawed and then homogenized by gentle 
pipetting. For the luciferase activity, 10 µL of 
lysate from each well was transferred to an 
opaque plate. Luminescence was then measured 
after adding 50 µL of luciferase substrate to the 
cells using SpectraMaxL microplate reader 
(SoftMax Pro 5.4.4 software, Molecular Devices) 
and activity was detected in relative light units 
(RLU).  
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BHK-15 cells at 90 % confluence were treated 
with gedunin, diluted in 2 % FBS-MEM, for the 
same range of concentrations as used for 
replicon assays in a 96-well plate, and incubated 
at 37 °C in the presence of 5 % CO2. At 48 h 
post-treatment, the compound dilutions were 
aspirated from the cells, and washed with MEM. 
Cell toxicity of the compound was then measured 
using Quick Cell Proliferation Assay kit. 
Substrate from the kit was diluted appropriately 
and 100 µL of the substrate was added to each 
well. Plate was then incubated at 37 °C for 2 h 
and the optical density (OD450)was measured 
using a microplate reader, SpectraMax M5 
(SoftMax Pro 4.8 software, Molecular Devices). 
The OD450 obtained for cells treated with the drug 
dilutions were compared to the cells treated with 
1 % DMSO alone as negative control. 
 
Molecular docking studies 
 
Preparation of ligand 
 
Chemical structure of gedunin was obtained from 
PubChem chemistry database, which has been 
reported to inhibit Hsp90 protein [8]. The 
structure of the compound was then drawn in 
ChemSketch software 11.02 (Advanced 
Chemistry Development, Inc. ACD/Labs) and 3-D 
structure optimization was done by adding 
hydrogen atoms to the ligand. The refined 
structure was saved in .mol format and then 
converted to pdb file format using ArgusLab 4.0.1 
(Mark Thompson and Planaria Software LLC). 
Then torsions of the ligand were stabilized, non-
polar hydrogens were added and PDBQT file 
was prepared using AutoDock Tool for further 
analysis through molecular docking.  
 
Preparation of Hsp90 as a target protein 
 
The structure of Hsp90 in complex with ADP in 
the N-terminal ADP/ATP binding site (PDB ID: 
1AM1) was retrieved from RSCB Protein Data 
Bank [17]. Ligand molecule was initially removed 
for the purpose of docking. The protein structure 
was adjusted and optimized by adding hydrogen 
atoms and removing water molecules using 
AutoDockTools 1.5.6 (The Scripps Research 
Institute, La Jolla, USA). The grid box for the 
receptor was then set to cover the entire 
molecular surface and the output file was 




Molecular docking was then initiated using 
AutoDock Vina 1.1.2 [18] and the predicted 
binding affinity of the ligand with the receptor was 
calculated based on the scoring function in 
kcal/mol. After docking, the docked complex 
having a conformation with the lowest binding 
affinity value was selected and saved in pdb 
format. The docked complexes were analyzed 
using UCSF Chimera version 1.8.1 (Resource for 
Biocomputing, Visualization, and Informatics at 
the University of California, San Francisco). Two-
dimensional and three-dimensional interaction 
patterns of the docked complex were determined 
in order to study the amino acids involved in the 





The RLU values from the luciferase assay were 
plotted against the log transformation of the 
compound concentrations and the effective 
concentration (EC50) was determined using 
GraphPad Prism version 5 software (GraphPad 
Software, San Diego California, USA). Data are 
presented as mean ± standard deviation (SD, n = 
3). The data were evaluated statistically using 
one-way analysis of variance (ANOVA) and p < 




Inhibition of dengue virus subgenomic 
replicon in cell culture 
 
The inhibitory activity of gedunin was evaluated 
against DENV replication in a replicon based 
assay. Here, four different dilutions of the 
compound (1, 10, 50 and 100 µM) were tested 
against dengue virus replication using the DENV 
replicon containing the reporter gene (R. 
luciferase), while DMSO (1 %) treated cells were 
used as negative control in the inhibition assays. 
Luciferase assays were performed with the cell 
extracts using standard R. luciferase substrate. 
Cells treated with 1 % DMSO were used as 
negative control for inhibition. The relative light 
units (RLU) were plotted against the log 
transformation of the concentrations of the 
compound and a concentration dependent virus 
inhibition was observed (Figure 1). Upon an 
increase in the concentration of gedunin, a 
significant reduction of reporter activity was 
observed and almost complete inhibition was 
observed at higher concentrations such as 50 
and 100 µM. EC50 value was determined using 
GraphPad Prism software. Gedunin exhibited 
significant reduction in the luciferase activity 
compared with the control indicating the inhibition 
of genome replication with EC50 of 10 µM. 
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Figure 1: Inhibitory activity of gedunin against 
DENV-R.luc2A-RP replicon. Test concentrations 
indicating significant inhibition are represented by 
asterisk; *p < 0.05 using one way ANOVA). Mock 
indicates treatment with 1 % dimethyl sulfoxide; n 
= 3; error bars indicate standard deviation 
 
Each of these compound concentrations were 
then tested for cytotoxicity in BHK-15 cells at 90 
% confluence using the quick cell proliferation 
assay. Cytotoxicity assays were also performed 
for each concentration in a 96 well format and 
optical densities were determined at 450 nm 
using micro-titer plate reader. The optical 
densities obtained with the drugs were compared 
with that of the DMSO treated and untreated 
cells and there was no toxicity observed within 
the range of the concentrations used up to 100 
µM. 
 
Gedunin-Hsp90 docking results 
 
Gedunin was selected as the ligand for this study 
on the basis of its previous roles in modulation of 
the Hsp90 activity in cancers and antiviral 
studies. Structures of gedunin (Figure 2) and 
Hsp90 (PDB: 1AM1, Figure 3) were processed 
for computational analysis using AutoDock Tool, 
then gedunin was docked withHsp90 at its N-
terminal binding pocket using AutoDock vina.  
 
 
Figure 2: Structure of gedunin 
 
 
Figure 3: Crystal structure of Hsp90 (PDB 1AM1) 
 
Initially, the protein with attached ATP in the N-
terminal domain was selected for analyzing 
whether the ligand binds in the ATP binding site 
or not. The ligand was later removed using 
Chimera software. These docking results showed 
that gedunin successfully binds in the ATP 
binding pocket of the Hsp90 molecule at N-
terminal (Figure 4). Thus, the active conformation 
of the ligand and the best binding mode for the 
active site cavity were obtained. The 
conformation of the docked complex with the 
lowest binding energy values was selected and 
saved in pdb format. According to the docking 
results, gedunin exhibited a good average 
binding affinity (-8.9 kcal/mol) and interacted 
potentially with the amino acids within the binding 
pocket of the Hsp90 at its N-terminal. 
 
               
     A                          B 
Figure 4: Three dimensional representation of the binding pocket. (A) Surface representation of the N-terminal 
ATP-binding site of Hsp90 with the bound ATP molecule (B) AutoDock predicted model of bound conformation of 
the compound gedunin at the ATP binding site of Hsp90 that demonstrated dengue antiviral activity in cell culture 
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                    A 
 
                      B 
Figure 5: The interaction pattern of gedunin with the active site of host chaperone Hsp90 (PDB 1AM1) generated 
by the program, Discovery Studio 4.1.0. (A) Two dimensional interaction of the protein-ligand complex. The 
legend inset represents the type of interaction between the ligand atoms and the amino acid residues of the 
protein. (B) Three dimensional docking of the compound in the binding pocket showing the hydrogen bond 
interactions 
 
The possible protein-inhibitor interactions of 
gedunin with the active site of Hsp90 molecule 
are shown in Figure 5A. Amino acid residues at 
the binding site interacting with the gedunin are 
Asn 37, Asp 40, Ala 41, Lys 44, Ile 82, Gly 83, 
Met 84, Asn 92, Leu 93, Lys 98, Gly 121, Val 
122, Gly 123, Phe 124, and Thr 171. The 
compound also formed potential hydrogen bond 
interactions with the amino acids at the active 
site (Figure 5B). Amino acid residues involved in 
hydrogen bonding are Asn 37, Ala 41, Met 84, 
GLy 123, Phe 124, and Thr 171. 
DISCUSSION 
 
The aim of our work was to evaluate the antiviral 
property of the compound gedunin from the 
Indian neem plant against dengue virus and 
propose its potential mechanism of action 
through molecular docking studies. Gedunin has 
been shown to bind to the host chaperone 
machinery of Hsp90 and blocks its activity [14]. 
Hsp90s are host chaperone proteins which act 
as ATPases and consists of homodimeric 
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complexes. Each monomer consists of a C 
terminal domain involved in dimerization, a 
middle domain and an N-terminal ATP binding 
domain [19]. Hsp90 plays important role in 
helping mutated proteins in several cancers. It is 
involved in stabilization of a number of oncogenic 
kinases, including HER2, EGFR, BCR-ABL, B-
Raf and EML4-ALK [20]. The host protein Hsp90 
plays an essential role in the replication of 
various viruses, making it an important target for 
antiviral drugs. An antibiotic geldanamycin (GA), 
which was initially characterized as an anticancer 
agent, has been reported to exhibit broad-
spectrum antiviral activity in vitro against several 
viruses by targeting the ADP/ATP binding site of 
Hsp90 [21]. The target viruses include herpes 
simplex virus type-1 (HSV-1) [10], severe acute 
respiratory syndrome corona virus, vaccinia virus 
[23], influenza virus, vesicular stomatitis virus 
[22], hepatitis C virus [24] and ebola virus [11].   
 
Gedunin, identified as HSP-90 inhibitor was 
therefore tested against the dengue replicon in 
vitro in BHK-15 cells. Development of 
subgenomic replicons of the virus offer great 
potential to study the replication process, as well 
as to study the effects of antiviral drugs/ 
inhibitors on the replication due to their non-
infectious nature [25]. Different concentrations of 
the compound gedunin were tested against 
dengue virus replication using the DENV 
replicon, containing the reporter gene (R. 
luciferase) expressed in a replication dependent 
manner. It was observed that gedunin 
significantly reduced replication of dengue virus 
in cell culture. The exact mechanism of antiviral 
action of gedunin is not very clear yet. Several 
studies have shown that it inhibits the activity of 
the host chaperone Hsp90. Hsp90 has been 
believed to facilitate viral protein folding and 
activity of non-structural proteins such as 
polymerase, protease and helicase as well as the 
structural proteins [3]. The polymerase of several 
viruses require Hsp90 for genome replication 
which include influenza virus A [12], herpes 
simplex virus [26], flock house virus [27] and 
vesicular stomatitis virus and treatment with 
Hsp90 inhibitors such as geldanamycin and 17-
AAG lead to degradation of polymerase 
complexes [28,22]. 
 
Molecular docking analysis was then carried out 
using AutoDock vina software to evaluate the 
binding capability of gedunin with Hsp90 
molecule and propose its possible mechanism of 
action. The obtained results suggested that the 
Hsp90 inhibitor gedunin directly binds in the N-
terminal ATP binding site of the protein and 
forms significant non-covalent and hydrogen 
bond interactions. In a study with geldanamycin, 
it was shown that the compound binds 
specifically in the ATP/ADP binding site of Hsp90 
and inhibits the protein function. In a study 
conducted by Petrikaite and Matulis [7], they also 
suggested that the majority of Hsp90 inhibitors 
blocks ATPase activity of Hsp90 by binding in the 
N-terminal ATP. These results correlate with the 
findings of the computational analysis of the 
inhibitor and the host chaperone in the current 
study. Recently, Hsp90 was shown to be an 
essential host protein for the replication of 
several negative strand RNA viruses [11]. Other 
studies have shown that host factors are involved 
in JEV life cycle and RNA virus replication and 
identified other host factors such as Hsp70 and 
GRP78 including Hsp90 in the secretion medium 




Using in vitro technique and molecular docking 
studies, a novel compound that inhibits DENV 
replication has been successfully identified. The 
findings of the study indicate that gedunin has a 
significant inhibitory activity against dengue virus 
in vitro and may prove to be a good lead 
compound for the development of an anti-dengue 
compound targeting the Hsp90 protein. Further 
investigations on the mechanism by which 
gedunin induce client protein degradation and 
inhibits dengue virus in vitro are required. 
Furthermore, the approach used in the present 
study may afford additional drug candidates for 
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